Use your antibodies-online credentials, if available.
No Products on your Comparison List.
Your basket is empty.
Find out more
The protein encoded by DPYD is a pyrimidine catabolic enzyme and the initial and rate-limiting factor in the pathway of uracil and thymidine catabolism. Additionally we are shipping DPYD Antibodies (53) and DPYD Proteins (7) and many more products for this protein.
Showing 10 out of 35 products:
General DPYD ELISA Kit for Competition ELISA - ABIN1129485
Abuohashish, Al-Rejaie, Al-Hosaini, Parmar, Ahmed: Alleviating effects of morin against experimentally-induced diabetic osteopenia. in Diabetology & metabolic syndrome 2013
Show all 2 references for ABIN1129485
Human DPYD ELISA Kit for Sandwich ELISA - ABIN414994
Li, Dong, Zhao, Tang, Chen, Ding, Men, Luo, Du, Ge, Tan, Cao, Liu: The upregulation of dihydropyrimidine dehydrogenase in liver is involved in acquired resistance to 5-fluorouracil. in European journal of cancer (Oxford, England : 1990) 2013
Reprot strong functional effect of a DPYD haplotype upon a phenotypic marker of individual 5-FU metabolism to improve toxicity prediction.
we believe that developing functional testing at the bedside could probably help to better picture the actual DPD status of patients scheduled for fluorouracil-based therapy, so as to propose subsequent appropriate adaptive dosing strategies.
DPYD genotyping for alleles 7, *2A, *13 and Y186C was not helpful in the identification of patients with severe DPD deficiency in this series of patients
Our results revealed that the C allele of the DPYD 85T > C polymorphism might be associated with susceptibility to pediatric acute lymphoblastic leukemia
Increases in gene expression levels of TYMP (show TYMP ELISA Kits), DPYD, and HIF1A (show HIF1A ELISA Kits) in tumor tissues at 7 days after the start of CRT (show SLC6A8 ELISA Kits) may be useful for predicting the efficacy of CRT (show SLC6A8 ELISA Kits) including S-1 or UFT
There were not statistical significant differences between carriers of KRAS mutated alleles between SD and PD groups. No significant difference was found between response rates and toxicity and DPD or UGT1A1 (show UGT1A1 ELISA Kits) genotypes. Our results suggested that determination of DPD or UGT1A1 (show UGT1A1 ELISA Kits) genotypes could not be useful for predicting severe toxicity of irinotecan in our population.
Study shows that somatic mutations of DPYD cause a switch in pyrimidine metabolism and promote gene expression of pyrimidine enzymes toward malignant progression.
Results suggest that DPYD c.1129-5923 C>G/hapB3 have limited predictive value for severe toxicity to 5-FU based combination chemotherapy.
oxaliplatin-based chemotherapy increases ERCC1 (show ERCC1 ELISA Kits) and DPYD expression levels; bevacizumab induces VEGFA (show VEGFA ELISA Kits) expression in metastatic colorectal cancer
This study demonstrates the clinical validity of combined MIR27A/DPYD screening to identify patients at risk of severe FP-toxicity.
DPD gene expression is regulated first at the mRNA level when the hepatocytes enter the cell cycle. There is little regulation at the translational level. Cell proliferation rate is influences the enzyme activity modification.
Data show that dihydropyrimidine dehydrogenase residue H673 is required for active site closure, while S670 is important for substrate recognition.
The protein encoded by this gene is a pyrimidine catabolic enzyme and the initial and rate-limiting factor in the pathway of uracil and thymidine catabolism. Mutations in this gene result in dihydropyrimidine dehydrogenase deficiency, an error in pyrimidine metabolism associated with thymine-uraciluria and an increased risk of toxicity in cancer patients receiving 5-fluorouracil chemotherapy. Two transcript variants encoding different isoforms have been found for this gene.
, dihydropyrimidine dehydrogenase [NADP(+)]
, dihydrothymine dehydrogenase
, dihydrouracil dehydrogenase
, dihydropyrimidine dehydrogenase